The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.
about
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsReconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomesDeciphering the role of nuclear and cytoplasmic IKKα in skin cancerChronic graft loss and death in patients with post-transplant malignancy in living kidney transplantation: a competing risk analysis.Primary care of the renal transplant patient.Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer developmentThe epidemic of nonmelanoma skin cancer and the widespread use of statins: Is there a connection?Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial.A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progressionIncidence of malignancy after living kidney transplantation: a multicenter study from iran.Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.Association of CKD and cancer risk in older peopleColon and rectal cancer after renal transplantation.A comparison of rat chronic progressive nephropathy with human renal disease-implications for human risk assessment.Skin changes following organ transplantation: an interdisciplinary challenge.Optimal management of skin cancer in immunosuppressed patients.Malignancies after kidney transplantation: a 40-year single-center experience in Korea.A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.Free tissue transfer for head and neck reconstruction in solid organ transplant patients.Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study.Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cellsOverexpression of vascular endothelial growth factor and the development of post-transplantation cancerDe novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression.Late onset epstein barr virus seropositive posttransplant lymphoproliferative disorder in two renal transplant receivers.Renal carcinogenesis after uninephrectomy.Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.[Tumor and transplantation].Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States.Cancer risk with alemtuzumab following kidney transplantation.Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.Carcinoma of the Tongue in Renal Transplant Recipients: An Unusual Spectrum of De novo Malignancy at a Tertiary Care Center in India Over a Period of 26 Years.Post-transplant malignancy: a burdensome complication in renal allograft recipients in Korea
P2860
Q24187213-DDB82772-7A6E-44D7-9CF6-0FDF57556512Q28080994-1DB2FE35-94B5-4BCF-9E47-9DF1EF0A39E2Q28828173-FE211FDD-033B-40DE-94B6-6A9ED2843DD4Q33876782-35E9CF77-8998-4AB1-B152-3A162ED31248Q33898744-F5B0EBF5-8FA3-4173-BCF4-5B962D19E444Q33943659-07DE770F-2C39-4E9F-A3B3-7C9285AF65FAQ34009025-5418A134-236E-4E51-8D51-011B7123D152Q34055699-1F496D1C-0CC9-4116-B4F7-B85C7A32E5E6Q34891079-D73D8C53-8CBC-47E1-9353-9F69F6C58DF6Q35022430-BBF461EB-2005-4F1C-8C4B-03CFB896F736Q35584849-90FC3C7A-918F-4265-866F-B07FB609B952Q35973628-A25825DA-CF38-42BB-82EA-0045703C7F0CQ36037651-9457F6D4-EB5A-4B42-919C-2AC29E6A28EBQ36985818-C508C5A5-FC03-4F18-8B51-96E2AE6DB742Q37112443-651C3C1C-609F-4699-9607-165DD6EBDD27Q37211112-8740EB3D-7883-4CA8-800C-D1B367765774Q37242687-2078E677-FC31-4F77-9AA4-108FA2034B40Q37514291-74E11152-70FF-4714-A2C4-7702A86D8CE0Q37687958-E5ACD7EE-E20A-419F-B62A-EC58C8709AFFQ38228585-3E5B6BD7-335A-474F-B235-05E5E0F479E0Q38474214-C903183B-8CE2-40AF-8806-86D977227FB9Q38619244-1F7D6E6B-CA28-4BE4-BAB8-10F9CF817382Q38830835-BBA8823F-DC96-4074-B821-CDCE6B412367Q39260307-22108D0A-13C0-4D9A-A196-71FE66E1E628Q39716989-2DF6928C-D3E6-4325-AB56-ED0B8FAB230DQ39776480-8434C729-4C05-4D1A-98EA-5715756309D2Q39960762-37F42951-238B-44A4-B585-82C808D50620Q41227335-9A62C892-F2F2-4990-8F64-53421A220620Q41846519-143B857E-DF90-4F89-8349-A958A6906B0CQ42172906-F2A858EB-84B8-42EE-8B0A-6EE1F62C6ED9Q42503484-692B743D-BC93-4601-928D-C546CD5D31F9Q44398159-E32D3A9C-0FE0-4C6A-9AFF-758C542B3DEEQ44547715-52A4DB86-B8D1-4327-9477-DBEAEAD4FB00Q45069301-F90E901D-10B2-4EB4-B66F-C4AF2DD5EEC8Q50866852-70773EAC-236C-4682-975F-07A098CD6C69Q53550694-4EAF4A96-3BAD-49D8-8E5A-CE1916C0A775Q55265769-F477CC69-2743-4415-AAD3-333CCA177CF0Q55339839-A11ABB0E-8A8F-4DD6-B710-6D9890620640Q57223044-ACDF34CD-99C2-433E-B9D0-E44303706413
P2860
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The janus face of immunosuppre ...... Transplantation Center Munich.
@en
type
label
The janus face of immunosuppre ...... Transplantation Center Munich.
@en
prefLabel
The janus face of immunosuppre ...... Transplantation Center Munich.
@en
P2093
P356
P1433
P1476
The janus face of immunosuppre ...... Transplantation Center Munich.
@en
P2093
Arbogast H
P2888
P304
P356
10.1038/SJ.KI.5002154
P407
P577
2007-02-28T00:00:00Z